Q-omics provides the consensus-scored C20orf144 profile across patient tissues and cancer cell-line models. C20orf144 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C20orf144 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, C20orf144 RNA expression shows 18,629 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where C20orf144 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C20orf144 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C20orf144 survival associations across molecular data types. C20orf144 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C20orf144 RNA expression–survival associations across cancer types. High C20orf144 expression shows unfavorable associations in UVM, MESO, ACC, KIRC, LGG and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for C20orf144 RNA expression.
This table summarizes C20orf144 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for C20orf144. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C20orf144 shows higher tumor expression in HNSC, COAD, BLCA, LIHC, STAD and LUSC. The HNSC box plot shows higher C20orf144 RNA expression in tumor versus normal tissue (log2 FC = +0.416, t-test p < 0.001).
This table shows molecular features associated with C20orf144 in patient tissues and cancer cell lines. In patient samples, C20orf144 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C20orf144 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
